Fulgenzi, C. A. M., Cheon, J., D'Alessio, A., Nishida, N., Ang, C., Marron, T. U., Wu, L., Saeed, A., Wietharn, B., Cammarota, A., Pressiani, T., Personeni, N., Pinter, M., Scheiner, B., Balcar, L., Napolitano, A., Huang, Y., Phen, S., Naqash, A. R., Vivaldi, C., Salani, F., Masi, G., Bettinger, D., Vogel, A., Schönlein, M., von Felden, J., Schulze, K., Wege, H., Galle, P. R., Kudo, M., Rimassa, L., Singal, A. G., Sharma, R., Cortellini, A., Gaillard, V. E., Chon, H. J., & Pinato, D. J. (2022). reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. European journal of cancer, 175, 204–213. http://access.bl.uk/ark:/81055/vdc_100168342585.0x00001f